Navigation Links
BD Diagnostics Hires Leading Infectious Disease Diagnostics Expert to Strengthen New Product Pipeline
Date:7/6/2011

SPARKS, Md., July 6, 2011 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today that Patrick R. Murray, Ph.D. joined the Company as Worldwide Director, Scientific Affairs, Diagnostic Systems.

Dr. Murray brings experience from an esteemed career in academics and clinical practice, most recently serving as Chief of the Microbiology Service and Senior Scientist at the National Institutes of Health (NIH) Clinical Center.

BD Diagnostics has a rich history of providing first-to-market diagnostic solutions and is currently focused on identifying and developing innovative technologies in Infectious Disease, Women's Health and Cancer Diagnostics.

In his new role, Dr. Murray will leverage his clinical expertise to best define new product requirements, evaluate new technologies and engage external experts and institutions in BD's innovation process. He will be based in the Company's Sparks, MD office.

"We are very pleased to have a leading expert in infectious disease diagnostics, such as Dr. Murray joining our team," said Tom Polen, President of BD Diagnostics - Diagnostic Systems. "His clinical perspective will be a great addition to BD as we continue to pursue new breakthrough diagnostic solutions."

While at NIH, Dr. Murray oversaw the clinical and research programs in Microbiology as well as postdoctoral training of Ph.D. and M.D. microbiology and infectious disease fellows. He received the NIH Clinical Center Director's Award for Patient Care and the NIH Director's Award for Clinical Research. Prior to NIH, Dr. Murray served as a Professor and Head of Clinical Microbiology at the University of Maryland Medical Center and as Professor in the Department of Medicine & Pathology at Washington University in Saint Louis. He received his Ph.D. degree in Microbiology at UCLA and conducted postgraduate training in Clinical Microbiology at the Mayo Clinic in Rochester, MN.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Jamie Yacco
Public Relations
(201) 847-4796
Jamie_Yacco@bd.com


'/>"/>
SOURCE BD-Becton Dickinson
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
2. Medical Devices & Diagnostics Equipments in India
3. Reportlinker Adds HIV Diagnostics Market in India
4. DeviceSpace Campaign Features Medical Device and Diagnostics Companies
5. Reportlinker Adds Global Hemostasis Diagnostics Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
6. Quest Diagnostics Wins Gold Medical Design Excellence Award (MDEA) for Diagnostic Innovation
7. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
8. Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year
9. Quest Diagnostics to Speak at the Jefferies 2011 Global Healthcare Conference
10. Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer
11. Boston Heart Lab Changes Name to Boston Heart Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):